Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* TTP with platelets less than 100,000 and microangiopathic hemolytic anemia~* Age greater than 18 and less than 60~* LDH \> 2x upper limit of normal~* PT and PTT normal~* Patients must give signed informed consent~* Pre-menopausal woman must have negative pregnancy test.~* TTP not related to underlying cancer, treatment of cancer or transplantation.~* TTP not associated with drugs.~Exclusion Criteria:~* LFTs AST/ALT \> 2x upper limit of normal~* Hepatitis B and Hepatitis C infection.~* HIV with active opportunistic infections~* Acute or chronic Disseminated Intravascular Coagulation (DIC), defined as D-dimer 8ug/ml and fibrinogen\<100 mg/dl~* TTP related to drugs, malignancy and transplantation.~* Pregnancy~* Concurrent other investigational drug use during this study.~* Porphyria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Danazol, Plex, Steroids (Type: EXPERIMENTAL): Everyone will receive Danazol with plasma exchange and corticosteroids
- Historic Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).